Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Ulcerative colitis is an inflammatory bowel disease that is characterized by chronic inflammation of the colon. The direct cause of the disease is unknown, but patients are commonly treated with ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

Patients in the virtual weight management programs will now have access to Eli Lilly’s reduced-cost GLP-1 in doses from 2.5 mg to 15 mg and single vial and single pen injections. Lilly recently ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Insulin Pens market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036" report has been added ...

Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is making larger doses available for $499 through its self-pay program.

Eli Lilly wants the most optimal locations to host its new manufacturing facilities in the U.S.—and it’s open to pitches. The Indianapolis pharma has established an online portal to accept ...